



Statin resistance and export

Frandsen, Rasmus John Normand; Ley, Ane; Naesby, Michael

Publication date:
2015

Document Version
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

Citation (APA):
Frandsen, R. J. N., Ley, A., & Naesby, M. (2015). Statin resistance and export. (Patent No. WO2015161856).

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



- (51) **International Patent Classification:**
A61K 36/06 (2006.01) *A61K 31/20* (2006.01)
A61K 31/366 (2006.01)
- (21) **International Application Number:**
 PCT/DK2015/050098
- (22) **International Filing Date:**
 16 April 2015 (16.04.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
 14165696.7 23 April 2014 (23.04.2014) EP
- (71) **Applicant:** DANMARKS TEKNISKE UNIVERSITET [DK/DK]; Anker Engelundsvej 1, Bygning 101A, DK-2800 Lyngby (DK).
- (72) **Inventors:** FRANDBSEN, Rasmus John Normand; En-evangen 55, DK-3450 Allerød (DK). LEY, Ane; Dronningens Vænge 12, 2.tv., DK-2800 Kgs. Lyngby (DK).
- NAESBY, Michael; 2, Rue de l'hotel de ville, F-68330 Huningue (FR).
- (74) **Agent:** PLOUGMANN & VINGTOFT A/S; Rued Langgaards Vej 8, 2300 Copenhagen S (DK).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

[Continued on next page]

(54) Title: STATIN RESISTANCE AND EXPORT




Figure 3:
Investigation of the potential of MicE to confer the resistance to statins in yeast

(57) **Abstract:** The present invention relates e.g. to methods of producing statins in transgenic, non-filamentous microorganisms such as *Saccharomyces cerevisiae*. In addition, the present invention relates to the transgenic, non-filamentous microorganisms as such as well as various uses of transmembrane statin efflux pump(s) originating from various filamentous fungi. Moreover, the present invention relates to the transferring the compactin, lovastatin or monacolin K gene cluster originating from non-filamentous fungi into easily fermentable microorganisms, followed by expression or overexpression of the efflux pump encoding genes in said microorganisms in order to increase the microorganisms resistance to statins which in turn allows for production of elevated concentrations of natural statins compared to statin-producing methods known in the art.



TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

STATIN RESISTANCE AND EXPORT

Technical field of the invention

5 The present invention relates e.g. to methods of producing statins in transgenic, non-filamentous microorganisms such as *Saccharomyces cerevisiae*. Further, the present invention relates to the transgenic, non-filamentous microorganisms as such as well as various uses of transmembrane statin efflux pump(s) originating from various filamentous fungi.

10

Background of the invention

Statins are important inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR), the regulatory and rate-limiting enzyme in the mevalonate
15 pathway, which leads to the production of sterols, such as cholesterol in human, and ergosterol in fungi.

The blood cholesterol level in mammals is a result of *de novo* synthesis and dietary intake. Elevated levels of blood cholesterol often lead to atherosclerosis,
20 i.e. deposits of LDL particles on the inside of the arterial walls, leading to various cardiovascular diseases. Treatment of elevated cholesterol levels is typically a combination of dietary changes and medical treatment with statins to control *de novo* synthesis.

25 With their effective cholesterol-lowering ability, statins have been widely used as hypercholesterolemia drugs to prevent and treat cardiovascular diseases and has become one of the best-selling pharmaceuticals in the past decade.

Typically, statins are divided into three classes based on their mode of synthesis:
30 natural, semi-natural and synthetic. Natural statins, such as lovastatin/monacolin K and compactin, are synthesised via the polyketide biosynthetic pathway by filamentous fungi including *Aspergillus terreus*, *Monascus purpureus* and *Penicillium citrinum*. The natural statin compounds are utilized by the fungi to inhibit the growth of eukaryotic competitors that inhabits the same
35 ecosystems/niche. Semi-natural statins are natural statins, which post-purification

has been modified through synthetic chemistry or via a biotransformation. The synthetic statins differ significantly in structure from that of the natural and semi-natural statins and are produced by chemical synthesis.

5 More specifically, the two known natural statins, compactin and lovastatin, are produced as secondary metabolites by filamentous fungi; compactin is produced by *Penicillium* species, e.g. *P. solitum* and *P. brevicompactum*, whereas lovastatin is produced by *Aspergillus* and *Monascus* species, e.g. *A. terreus*, *M. purpureus* and *M. pilosus*.

10

In general, bioactive secondary metabolites often provide a selective advantage to the producing microorganism in their natural environment. However, said metabolites can also be toxic to the producing microorganisms if they themselves contain the target site of the compound. Therefore, the secondary metabolite biosynthesis gene clusters, in addition to the biosynthetic enzymes, often also contain genes encoding a secretion system(s), which in addition can provide a resistance mechanism to prevent self-intoxication.

This is also the case in relation to both the compactin and the lovastatin biosynthesis gene clusters, where putative efflux pump genes have been identified, namely the *mIcE* gene from the compactin biosynthetic gene cluster, *lovI* gene (also referred to in the art as: ORF10 or *lovH* - thus, for the purpose of simplicity the gene is hereinafter referred to as *lovI/H*) from the lovastatin gene cluster and *mokI* from the monacolin K cluster.

25

Well-known methods of producing natural statins, as well as their semi-synthetic derivatives, are mainly based on fermentation processes with strains of naturally statin-producing filamentous fungi.

30 Commercial production of natural and semi-natural statins is based on liquid fermentation of the relevant fungal species followed by purification and subsequent modification for the semi-natural statins. However, it is also well known that filamentous fungi are difficult to culture efficiently in fermenters, *inter alia* due to their unique physiology and morphology.

35

Hence, in order to overcome these problems and to increase the yields, several statin-manufacturing companies have switched to solid state fermentation, a challenging approach that is prone to contamination and involves a relatively high risk for the formation of undesirable side products. This is also well known in the art.

Also, it is well-known in the art that there is a common problem while fermenting statins in fungi as the final products are - besides being cholesterol lowering agents - also active antifungals and thereby limit the productivity in fungal hosts.

10 A possible solution to this problem could be to transfer the metabolic pathway to easily fermentable unicellular microorganisms, such as yeast. However, this solution is not easily achievable *inter alia* since yeast does not naturally produce any polyketides, which is one of the reasons why the relevant genes encoding the biosynthetic machinery for the formation of statins have to be functionally

15 expressed simultaneously at a balanced level. Additional challenges for producing statins in yeast include a limited availability of the necessary substrates (acetyl-CoA and malonyl-CoA) and co-factors (NADPH). Further challenges include problem with self-intoxication as yeast only has a basal level of statin-resistance (Riccardo & Kielland-Brandt, 2011).

20

Thus, in an effort to provide an alternative mode of biosynthesis, researcher has for the last decade been working on transferring the statin biosynthetic pathway from the traditionally used filamentous fungi into easily fermentable microorganisms such as *Saccharomyces cerevisiae*.

25

Xu W. et al. (2013), discloses *inter alia* the expression in yeast of the genes responsible for the biosynthesis of the lovastatin intermediate, monacolin J acid. However, the Xu W. et al. -article did not contain any disclosure of the expression of the statin efflux pump genes *mlcE*, *mokI* and/or *lovI/H* in e.g. *Saccharomyces*

30 *cerevisiae*, but merely discloses the expression of genes responsible for the biosynthesis of monacolin J acid which is an intermediate capable of being converted into the commercially attractive agent, simvastatin acid, in a single enzymatic step.

Abe et al. (2002) discloses *inter alia* that *mlcE* is a putative efflux pump which may be involved in conferring resistance to compactin as well as in metabolite secretion in the naturally producing microorganism (*Penicillium citrinum*). However, the Abe et al. -article contains no disclosure or suggestions of
5 transferring and/or expressing the *mlcE*, *mokI* or *lovI/H* genes in yeast, let alone in *Saccharomyces cerevisiae*.

An article by Hirata D., & Yano K. (1994), discloses *inter alia* that the *pdr5* gene encodes an efflux pump in *Saccharomyces cerevisiae*.

10

Likewise, in an article by Riccardo L., & Kielland-Brandt MC. (2011) is disclosed that *pdr5* gene encodes a pump that has shown to confer basic-level of statin-resistance in *Saccharomyces cerevisiae*. Also disclosed in said article is the susceptibility to lovastatin of *Saccharomyces cerevisiae* strains deleted for *PDR*
15 genes, i.e. genes encoding for drug resistance pumps responsible for exporting hydrophobic and amphiphilic drugs, such as lovastatin.

WO09133089 A1 disclosed *inter alia* a process for increasing the compactin, pravastatin, lovastatin and/or simvastatin productivity by a fermentation process
20 carried out with host organisms that are genetically engineered to have increased resistance to said statins. More specifically, a process is provided which makes use of microorganisms (preferably *Penicillium chrysogenum*) in which genes encoding proteins which mediate statin resistance are overexpressed. Also disclosed in
WO09133089 A1 is the compactin biosynthetic gene cluster of *Penicillium citrinum*
25 (i.e. *mlcA*, *mlcB*, *mlcC*, *mlcD*, *mIcE*, *mlcF*, *mlcH*, *mlcG*, *mlcR*) as well as the lovastatin biosynthetic gene cluster of *Aspergillus terreus* (i.e. *ORF1*, *ORF2*, *lovA*, *ORF5*, *lovC*, *lovD*, *ORF8*, *lovE*, *ORF10*, *lovF*, *ORF12*, *ORF13*, *ORF14*, *ORF15*, *ORF16*, *ORF18*). However, WO09133089 A1 contains no disclosure of neither the functions of said genes nor the transferring and expression of the statin efflux
30 pump encoding *lovI/H*, *mokI* or *mlcE* genes in *Saccharomyces cerevisiae*.

WO0129073A1 disclosed to the use of so-called MFS-transporters (named PUMPI and PUMP2) and their ability to confer resistance to otherwise toxic levels of lovastatin when expressed in *Saccharomyces cerevisiae*. However, as there is no
35 disclosure or suggestion in WO0129073A1 of transferring and expressing the

statin efflux pump encoding *lovI/H*, *mokI* or *mlcE* genes in *Saccharomyces cerevisiae*.

WO0037629 disclosed *inter alia* a method of increasing the production of
5 lovastatin in a lovastatin-producing or a non-lovastatin-producing microorganism.
ORF10 (*lovI/H*) is disclosed in WO0037629 as a gene relevant for the
transportation of metabolites. There is no disclosure in WO0037629 of *lovI/H*,
mokI or *mlcE*, let alone of the transfer and expression of said genes in a
Saccharomyces cerevisiae host e.g. for improving the statin resistance in said
10 host.

WO2009/077523 disclosed *inter alia* a method for the fermentative production of
e.g. compactin (mevastatin) and lovastatin where said method comprises
culturing a mutant host capable of producing e.g. lovastatin wherein the esterase
15 activity in said mutant host is more than 25% below the activity of said esterase
in the parent host. However, there is no disclosure in WO2009/077523 of e.g. the
mlcE, *mokI* and/or *lovI/H* genes encoding statin specific efflux pumps let alone of
transferring and expression of said genes in *Saccharomyces cerevisiae*.

20 WO2007147827 discloses *inter alia* *Saccharomyces cerevisiae* containing a
compactin biosynthesis gene and a gene for conversion of compactin into
pravastatin. The *mlcE* gene is disclosed as being one of these compactin
biosynthesis genes. There is no disclosure or suggestion in WO2007147827 that
e.g. *mlcE*, *mokI* and/or *lovI/H* is capable of encoding statin specific efflux pumps
25 in *Saccharomyces cerevisiae*, let alone of the transferring and expression of said
genes in *Saccharomyces cerevisiae*.

WO2010034686 discloses *inter alia* a method for the fermentative production of
e.g. compactin (mevastatin) and lovastatin where the method involves culturing a
30 host, e.g. *Saccharomyces cerevisiae*, e.g. by use of the *lovE* transcription
regulator gene. There is, however, no disclosure or suggestion in WO2010034686
of e.g. the *mlcE*, *mokI* and/or *lovI/H* genes is/are capable of encoding statin
specific efflux pumps in e.g. *Saccharomyces cerevisiae*, let alone of a transfer and
expression of said genes in *Saccharomyces cerevisiae*.

WO10069914 discloses a method for the fermentative production of e.g. compactin (mevastatin) and lovastatin where the method involves culturing a host, e.g. *Saccharomyces cerevisiae*, e.g. by use of specifically defined transcription regulator genes.

- 5 WO10069914 also discloses that *mlcE* encoding an efflux pump in *Penicillium citrinum*. However, WO10069914 contains no disclosure or suggestions that said efflux pump gene can be expressed in e.g. *Saccharomyces cerevisiae*.

As is apparent from the above-outlined prior art documents, the three genes
10 *mlcE*, *mokI* and *lovI/H* have not previously been characterized in depth, let alone when transferred into other host organisms. The article by Hutchinson et al. (2000), discloses the function of the *lovI* gene and states *inter alia* that heterologous expression of the putative lovastatin efflux pump gene *lovI* in
15 *Aspergillus nidulans* did not result in increased resistance to lovastatin in said host organism (no experimental data is provided in the article). Moreover, said article contains no disclosure of e.g. expressing the *mlcE*, *mokI* and/or *lovI/H* genes in yeast.

It is well known that statins are toxic for the statin-producing host cells, e.g. due
20 to the inhibition of ergosterol biosynthesis (fungal equivalent of cholesterol). It is therefore crucial to establish a nondestructive resistance mechanism in a given host cell (said host cell is also commonly referred to as a "cell factory") in order to establish a commercially profitable production of statins.

- 25 In order to avoid the undesirable effects of self-intoxication in the host cell several approaches has previously been utilized the most common being: 1) overexpression of the HMGR encoding gene and/or 2) development of a statin-insensitive HMGR.

30 The present invention relates to a novel approach for avoiding the undesirable effects of self-intoxication in easily fermentable host microorganisms by introduction of a transmembrane statin efflux pump in said microorganism for removing the toxic statins from said host.

This novel approach has the additional advantage that it also ensures the export out of microorganism of any produced statins, which *inter alia* eases the subsequent purification steps.

5 Hitherto, however, it has not been clear whether the putative efflux pumps from the statin biosynthetic gene clusters have the potential to export statins out of the statin-producing microorganisms. Thus, the inventors of the present application surprisingly found that introduction of genes encoding transmembrane statin efflux pumps, such as the *mlcE*, *mokI* and/or *lovI/H* gene(s) into statin sensitive
10 yeast hosts was indeed feasible and additionally found that said introduction turned out to increase the yeast`s resistance to statins present in the relevant growth media.

Hence, to summarize, there is a need for improvement in the art of the
15 productivity of fungal fermentations due the anti-fungal properties of statins. Drawbacks of the state of the art processes of producing statins – which are overcome by the present invention - involve *inter alia*:

(i) the fact that filamentous fungi, traditionally used for statin-production, are
20 difficult to culture efficiently in fermenters, *inter alia* due to their unique physiology and morphology.

(ii) the potential negative effects of the traditionally used method of overexpression of HMGR (in order to reduce statin self-intoxication) might have on the central metabolism of the host microorganism

25 (iii) the potentially deleterious effects of the statin self-intoxication of the statin-producing host microorganisms

(iv) the contamination problems and the risk of the formation of undesirable side products associated with the traditionally used "solid state fermentation" methods of producing statins. Moreover, it is well known in the art that collecting and/or
30 purifying the produced statin in the traditionally used "solid state fermentation" is both laborious and cost-ineffective.

Summary of the invention

The object of the present invention is *inter alia* to provide a method to solve some of the problems encountered in prior art processes of producing statins.

Preferably, a process is provided which makes use of easily fermentable
5 microorganisms, such as *Saccharomyces cerevisiae*, in which genes encoding statin efflux pumps are overexpressed.

Based on the hypothesis that the proteins MlcE, LovI/H and MokI - from the compactin, lovastatin and monacolin K gene clusters respectively - are in fact
10 transmembrane statin specific efflux pumps the inventors of the present application have successfully expressed and overexpressed e.g. the *mlcE* gene in different *Saccharomyces cerevisiae* strains and tested the responses of said strains to increasing statin levels.

15 Thus, the present invention relates to the transferring of the compactin, lovastatin or monacolin K gene cluster into easily fermentable microorganisms, such as *Saccharomyces cerevisiae*, followed by overexpression of the efflux pump encoding *mlcE*, *mokI* and/or *lovI/H* genes in said microorganisms.

20 This expression or overexpression turned out to increase resistance to statins in easily fermentable microorganisms such as, *Saccharomyces cerevisiae*, *Pichia pastoris* and *Schizosaccharomyces pomp*.

Moreover, the present invention relates to the use of the transmembrane statin
25 efflux pumps, such as MlcE, for increasing the resistance in transgenic microorganisms to the potentially deleterious effects of exogenous added statins on said microorganisms in connection with production of said statins in the organism.

30 This reduction of statin self-intoxication in the producing host microorganism allow for the production of elevated concentrations of natural statins compared to statin-producing methods known in the art. Moreover, overexpression in said hosts of the genes encoding the transmembrane statin efflux pumps, i.e. the *mlcE*, *lovI/H* and *mokI* genes, eliminates the potentially adverse effects of

overexpression the genes encoding the HMGR enzyme, i.e. one of the methods traditionally used in the art to produce statins in microorganisms.

Moreover, expression of the *mlcE*, *lovI/H* and *mokI* genes increased export of statins from the cytoplasm to the growth medium, easing purification of said
5 statins.

Definitions

Prior to discussing the present invention in further details, the following terms will
10 first be defined. In the context of the present application, the following terms have the following meanings. The below-outlined terms are listed in alphabetical order:

Activated lovastatin: Lovastatin, as well as other statins comprise of a lactone ring
15 unit, which can be present in an open or closed form, depending on the pH.

Statins are biologically active (i.e. are able to inhibit HMGR) only when their lactone ring is in an open confirmation (dihydroxy open-acid form). Activated lovastatin is lovastatin with an open lactone ring.

20 ARX3 strain: *Saccharomyces cerevisiae* strain originating from CEN.PK 113-11C strain with the efflux pump encoding gene *mlcE* from the compactin biosynthetic gene cluster integrated into the genome using method described by Mikkelsen et al., 2012.

25 Codon optimization: A codon is a DNA entity composed of three nucleotides that is being translated into a specific amino acid residue in a polypeptide chain. The Genetic code is degenerated, meaning that many amino acids can be encoded by more than one codon. Different organisms show preferences for particular codons that encode specific amino acids. Codon optimization is a method for optimizing
30 gene sequences in a way that the amino acid residues of the polypeptide chain are encoded by the codons preferred by the organism, in which we would like to express the gene.

Constitutive promoter (e.g. TEF1): Promoter that is active under all conditions in the cell. Gene expressed under a constitutive promoter is being continuously transcribed in the cell.

- 5 Crystal violet efflux pump (Sge1): Sge1 protein from *Saccharomyces cerevisiae* is a member of the drug-resistance protein family, and is capable of conferring resistance in yeast to crystal violet and other toxic substances.

C-terminal mRFP fusion: In order to determine subcellular localization of proteins,
10 the proteins can be tagged with a reporter protein, e.g. red fluorescent protein (RFP) at their C terminus or N terminus. Because of the ability of RFP to emit light when illuminated with light of a specific wavelength, the fused proteins can be tracked in cells using fluorescence microscopy.

- 15 "Drug:H⁺ antiporter 2 family": Drug:H⁺ antiporter 2 family is a family of multidrug resistance transport proteins from the major facilitator superfamily (MFS). Proteins in this family are membrane-bound enzymes containing 14 transmembrane spanning domains. They catalyze a reaction in which hydrogen protons and drugs are pumped in opposite direction across a membrane.

20

HC-toxin efflux pump (ToxA): ToxA protein form *Cochliobolus carbonum* is an HC-toxin efflux pump which contributes to self-protection against HC-toxin and/or secretion of HC-toxin into the extracellular environment.

- 25 HMGR: 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) is the rate-limiting enzyme in the mevalonate pathway, which leads to the production of sterols, such as cholesterol in human, and ergosterol in fungi. The enzyme is inhibited by products from the mevalonate pathways via a negative feedback loop.

- 30 Major facilitator superfamily (MFS): MFS is a family of membrane transport proteins that facilitate movement of small molecules across cell membranes in response to chemiosmotic ion gradients.

Mevastatin: also referred to in the art as compactin (and *ML-236B*) is a
35 hypolipidemic agent that belongs to the statins class.

MlcE topology: Topology describes the orientation of regular secondary structures, such as alpha-helices and beta strands in a protein structure and in relation to cell membranes. MlcE topology refers to the topology of the efflux pump MlcE.

5 mRFP: monomeric red fluorescent protein is a reporter protein used in fluorescence microscopy for subcellular localization of proteins to which mRFP is fused.

OD₆₀₀: Optical density (also called absorbance) is a measure of concentration of
10 cells in a suspension. It is determined in a spectrophotometer at a wavelength of 600 nm.

Overexpression: describes the various methods by which a gene or a protein can be modified in order to increase the concentration of active enzyme, including
15 *inter alia* (i) introduction of additional gene copies encoding host or heterologous proteins; (ii) overexpression of host proteins from a strong promoter; (iii) modifying the transcriptional regulation of the genes encoding enzymes mediating statin resistance; (iv) modifying the mRNA to increase the rate of translation initiation; (v) mutation of critical amino acids leading to proteins with improved
20 kinetic properties; (vi) mutations causing an increased half-life of the enzyme; (vii) modifying the mRNA molecule in such a way that the mRNA half-life is increased; Other methods which are well-known in the art may be envisaged.

pdr5 deletion strain (Pleotropic Drug Resistance gene): the *pdr5* gene encodes a
25 pump that has shown to confer a basic level of statin-resistance in *Saccharomyces cerevisiae*. The *pdr5* deletion strain (herein denoted as: *pdr5*Δ) does not contain said pump.

Plate dilution assay (spot assay): This assay allows testing of the toxic effects of
30 the compounds added to a solid growth medium. It is based on culturing a dilution series of a microorganism on said plates, following the growth of a microorganism and observing at which dilution the microorganism is unable to grow. The growth of individual microorganisms as a function of time is recorded by photography of the plates.

Penicillium citrinum: the compactin-producing filamentous fungi (also referred to in the art as *Penicillium solitum*)

Recombinant host strains: refers to host strains in which genetic material from
5 one or multiple sources have been brought together, creating sequences that would not otherwise be found in biological organisms.

RFP-tagged MlcE: To investigate subcellular localization of efflux pump MlcE, the relevant protein has been fused with RFP at its C terminus.

10

Standard Protein BLAST: Basic Local Alignment Search Tool is an algorithm for comparing biological sequence information. Standard Protein BLAST, available at e.g. <http://www.ncbi.nlm.nih.gov> is commonly used for identifying a query amino acid sequences in protein databases. The search tool is designed to identify local
15 regions of similarity.

Substantially homologous polynucleotide: A polynucleotide with nucleotide sequences that are substantially homologous to a reference sequence is defined as a polynucleotide with a nucleotide sequence with a degree of identity to the
20 specified nucleotide sequence of at least 80%, preferably at least 85%, more preferably at least 90%, still more preferably at least 95%, still more preferably at least 97%, still more preferably at least 98%, most preferably at least 99%

Substantially homologous polypeptide: A polypeptide with amino acid sequences
25 that are substantially homologous to a reference sequence is defined as a polypeptide with an amino acid sequence with a degree of identity to the specified amino acid sequence of at least 80%, preferably at least 85%, more preferably at least 90%, still more preferably at least 95%, still more preferably at least 97%, still more preferably at least 98%, most preferably at least 99%. Substantially
30 homologous polypeptides may for example contain only conservative substitutions of one or more amino acids of the specified amino acid sequences or substitutions, insertions or deletions of non-essential amino acids.

TEF promoter: constitutive promoter that regulates transcription of the
35 'Transcription Elongation Factor b' encoding gene

TOPCONS server: TOPCONS server is a tool for consensus prediction of membrane protein topology. It is available online at <http://topcons.net/>

Wild type strain: Reference *Saccharomyces cerevisiae* strain, in this study CEN.PK
5 113-11C (MATa MAL2-8C SUC2 his3 Δ ura3-52).

YPD agar plates: YPD is a complete medium for yeast growth composed of yeast extract, peptone and glucose. If YPD is used as a solid medium, agar is added to YPD, and the medium is solidified in plates for cultivation of microorganisms.

10

Advantages of the present invention

The inventors of the present application surprisingly showed that it is possible to use the transmembrane statin efflux pumps MlcE, LovI/H and MokI as a resistance
15 mechanism, i.e. for reducing the potentially deleterious effects of self-intoxication caused by the produced statins in a statin-producing microorganism, e.g. in yeasts such as *Saccharomyces cerevisiae*. This is a surprising finding in light of the prior art which e.g. suggested that this could not be the case as expression of the *mlcE* gene in e.g. the filamentous fungus *Aspergillus nidulans*, which is
20 normally sensitive to statins, did not increase its resistance against the tested compounds (see e.g. the article by Hutchinson et al., 2000).

An additional advantage of the present invention, in addition to providing resistance against both natural and semi-statins, is that the statin efflux pumps
25 also provides an elegant solution for exporting the produced statins into the extracellular medium in statin-producing hosts other than filamentous fungi, e.g. in yeasts such as *Saccharomyces cerevisiae*.

Furthermore, by expressing e.g. the *mlcE* gene in easily fermenting hosts such as
30 *Saccharomyces cerevisiae* there is no longer a need for the traditionally used overexpression of HMGR which in turn eliminates the potential negative effects that HMGR might have on the central metabolism of the host microorganism.

The above-mentioned statin pumps, e.g. MlcE, with their ability of exporting
35 natural and semi-natural statins across the plasma membrane has a great

potential for improving a statin-producing yeast cell factory. Not only do said pumps, e.g. MlcE, provide the resistance to a range of statins in yeast; it also ensures the export of the produced statins into the extracellular environment, which can significantly ease the subsequent purification of the produced
5 compounds compared to the traditionally used "solid state fermentation" methods based on naturally producing species of *Penicillium*, *Aspergillus* and *Monascus*.

Hence, the inventors of the present application provided evidence indicating that the polypeptides encoded by the *mlcE*, *LovI/H* and *MokI* genes are
10 transmembrane efflux pumps capable of transporting both natural and semi-natural statins out of the statin-producing host cell.

Moreover, the inventors of the present application showed that MlcE, LovI/H and MokI are statin-specific transporters, with the ability to transport compactin as
15 well as the compactin-related compounds lovastatin, simvastatin and pravastatin, across the plasma membrane. Therefore, in light of the above, overexpression of e.g. *mlcE* in statin-producing microorganisms, such as *Saccharomyces cerevisiae* could greatly improve the commercial production of natural and semi-natural statins compared to well-known statin-producing methods.

20 In general this means that the statin efflux pumps MlcE, LovI/H and MokI provide resistance to both, natural and semi-natural statins, making them great tools for optimizing e.g. yeast cell factories for statin production.

25

Detailed description of the invention

Thus, it is an object of the present invention to provide a statin producing method and statin producing transgenic, non-filamentous microorganisms that solves the above mentioned problems of the prior art.

30

Thus, one aspect of the invention relates to a method for the production of statin in a transgenic microorganism, wherein the method comprises expression in said microorganism of one or more polynucleotide(s) encoding one or more transmembrane statin efflux pump(s).

35

In a preferred embodiment, the polynucleotide(s) of said method are chosen from the group consisting of SEQ ID NOs: 1, 2, 3, 4 and/or 5.

In a further preferred embodiment, the polynucleotide(s) of said method is/are
5 chosen from the group consisting nucleotide variants comprising sequences with a degree of identity to any of SEQ ID NOs: 1, 2, 3, 4 and/or 5 of at least: 80%, preferably at least 85%, more preferably at least 90%, still more preferably at least 95%, still more preferably at least 97%, still more preferably at least 98%, most preferably at least 99%.

10

In an even further preferred embodiment, the polynucleotide(s) SEQ ID NOs: 1, 2, 3, 4 and/or 5 of said method is/are overexpressed.

In an even further preferred embodiment, the above-mentioned polynucleotide
15 variant(s) of SEQ ID NOs: 1, 2, 3, 4 and/or 5 is/are overexpressed.

Another aspect of the invention relates to a method for the production of statin in a transgenic microorganism, wherein the method comprises expression in said microorganism of polypeptide(s) chosen from the group consisting of SEQ ID NOs:
20 17, 18, 19 and/or 20.

In a further preferred embodiment, the polypeptide(s) of said method is/are chosen from the group consisting of variants comprising sequences with a degree of identity to any of SEQ ID NOs: 17, 18, 19 and/or 20 of at least: 80%,
25 preferably at least 85%, more preferably at least 90%, still more preferably at least 95%, still more preferably at least 97%, still more preferably at least 98%, most preferably at least 99%.

In an even further preferred embodiment, the polypeptide(s) of SEQ ID NOs: 17,
30 18, 19 and/or 20 of said method is/are overexpressed.

In an even further preferred embodiment, the above-mentioned polypeptide variants of SEQ ID NOs: 17, 18, 19 and/or 20 is/are overexpressed.

In an even further preferred embodiment, the transgenic microorganism for use in the production of statins is a non-filamentous fungus selected from the group consisting of *Saccharomyces cerevisiae*, *Pichia pastoris* and *Schizosaccharomyces pomp*.

5

In an even further preferred embodiment, the present invention relates to statins produced by any of the above methods.

Another aspect of the present invention relates to transgenic microorganism for use in the production of statin, wherein the microorganism comprises one or more polynucleotide(s) encoding one or more transmembrane statin efflux pump(s).

In a preferred embodiment, said transgenic microorganism comprises one or more polynucleotide(s) chosen from the group consisting of SEQ ID NOs: 1, 2, 3, 4 and/or 5.

In a further preferred embodiment, the transgenic microorganism comprises one or more nucleotide variant(s) comprising sequences with a degree of identity to any of SEQ ID NOs: 1, 2, 3, 4 and/or 5 of at least: 80%, preferably at least 85%, more preferably at least 90%, still more preferably at least 95%, still more preferably at least 97%, still more preferably at least 98%, most preferably at least 99%.

In an even further preferred embodiment, the transgenic microorganism comprises one or more polynucleotide(s) according to SEQ ID NOs: 1, 2, 3, 4 and/or 5 which is/are overexpressed.

In an even further preferred embodiment, the transgenic microorganism comprises one or more of the above polynucleotide variants of SEQ ID NOs: 1, 2, 3, 4 and/or 5 which are overexpressed.

In a preferred embodiment, said transgenic microorganism comprises one or more polypeptides chosen from the group consisting of SEQ ID NOs: 17, 18, 19 and/or 20.

35

In a further preferred embodiment, the transgenic microorganism comprises one or more polypeptide variant(s) comprising sequences with a degree of identity to any of SEQ ID NOs: 17, 18, 19 and/or 20 of at least: 80%, preferably at least 85%, more preferably at least 90%, still more preferably at least 95%, still more
5 preferably at least 97%, still more preferably at least 98%, most preferably at least 99%.

In an even further preferred embodiment, the transgenic microorganism comprises one or more polypeptide(s) according to SEQ ID NOs: 17, 18, 19
10 and/or 20, which is/are overexpressed.

In an even further preferred embodiment, the transgenic microorganism comprises one or more of the above polypeptide variants of SEQ ID NOs: 17, 18, 19 and/or 20, which is/are overexpressed.
15

In an even further preferred embodiment, the above transgenic microorganism is a non-filamentous fungus selected from the group consisting of *Saccharomyces cerevisiae*, *Pichia pastoris* and *Schizosaccharomyces pomp*.

20 Yet another aspect of the present invention relates to use of a transmembrane statin efflux pump in a transgenic non-filamentous statin-producing microorganism, for the production of statins in the microorganism and/or increasing the statin resistance in the microorganism and/or decreasing the statin self-intoxication in the microorganism and/or increasing the export of the
25 produced statins into the extracellular medium.

Also envisaged is the use of the statins obtained in any of the above-outlined methods in the production of a medicament.

30 A further aspect of the invention concerns a use of a transmembrane statin efflux pump in a microorganism, for the:
(i) bioconversion of statins in the microorganism and/or
(ii) increasing the statin resistance of the microorganism and/or
(iii) increasing the export of statins into the extracellular medium

35

An even further aspect of the invention concerns a polypeptide selected from the group consisting of SEQ ID NOs: 17, 18, 19 and/or 20 which, when incorporated into a transgenic non-filamentous microorganism, is capable of

- (ii) providing statin resistance in the microorganism and/or
- 5 (ii) exporting of the produced statins out of the microorganism

Also envisaged is one or more polypeptide variant(s) comprising a sequence with a degree of identity to any of SEQ ID NOs: 17, 18, 19 and/or 20 of at least: 80%, preferably at least 85%, more preferably at least 90%, still more preferably at
10 least 95%, still more preferably at least 97%, still more preferably at least 98%, most preferably at least 99% which, when incorporated into a transgenic non-filamentous microorganism, is capable of

- (ii) providing statin resistance in the microorganism and/or
- (ii) exporting of the produced statins out of the microorganism

15

A further aspect of the invention concerns a nucleic acid construct comprising any of the polynucleotide sequence according to SEQ ID NOs: 1, 2, 3, 4 and/or 5 operably linked to one or more control sequences that facilitate production of the polypeptide in an expression host.

20

An even further aspect of the invention concerns a recombinant expression cassette comprising said construct either maintained in the expression host as a self-replicating plasmid or integrated into the genome.

- 25 All patent and non-patent references cited in the present application, are hereby incorporated by reference in their entirety.

Brief description of the figures and the SEQ ID NOs

30

Figure 1:

Phylogenetic tree of representative members of the two families of MFS drug resistance proteins; family DHA1 with Drug:H⁺ antiporters consisting of 12 TMS and family DHA2 with Drug:H⁺ antiporters consisting of 14 TMS are shown. The
35 three putative statin efflux pumps (MlcE, LovI and MkiI from compactin, lovastatin

and monacolin biosynthetic gene clusters, respectively) are predicted to belong the DHA2 family. Protein sequences were obtained from UniProt Knowledgebase (UniProtKB, <http://www.uniprot.org/help/uniprotkb>), aligned with multiple sequence alignment tool MAFFT version 7 (Multiple sequence Alignment using Fast Fourier Transform) available at the European Bioinformatics Institute (<http://mafft.cbrc.jp/alignment/server/>). The tree was generated with ClustalW2 alignment program at EMBL-EBI using Neighbor-Joining clustering method (Setting: distance correction on, exclude gaps on), and viewed with FigTree software, version 1.4 (<http://tree.bio.ed.ac.uk/software/figtree>).

10

Figure 2:

Strain construction and subcellular localization of MlcE-RFP. A) Schematic representation of strain construction. Expression cassettes containing mlcE and its RFP-tagged version were integrated into the genome, under the control of the constitutive promoter TEF1 (strains ARX3 and ARX1, respectively). RFP alone has been expressed from the same locus and promoter, and the resulting strain (strain ARX2) was used as a control for fluorescence microscopy. B) Fluorescence microscopy results. For subcellular localization of the putative efflux pump MlcE strain ARX1, and a control strain ARX2 were incubated overnight in 10 mL of SC medium, shaking (150 rpm) at 30°C. Images obtained by differential interference contrast microscopy (DIC) (left panel) and corresponding fluorescence images (right panel) are shown.

20

25 Figure 3:

Investigation of the potential of MlcE to confer the resistance to statins in yeast. Tenfold dilution series of *Saccharomyces cerevisiae* WT and ARX3 strain harbouring the putative efflux pump MlcE, starting with an OD₆₀₀ of 0.02 were prepared from overnight cultures. 4.5 microliters of each dilution were plated on a set of YPD agar plates containing different cytotoxic compounds. The plates were incubated at 30°C for 2 days, after which the growth of the strains was recorded by photography.

30

Figure 4:

Investigation of the potential of MlcE to complement the PDR5 efflux pump in yeast. Fivefold dilution series of *Saccharomyces cerevisiae* WT, ARX3, AR29 pdr5 Δ and pdr5 Δ strains, starting with an OD₆₀₀ of 0.2 were prepared from overnight
5 cultures. Four microliters of each dilution were plated on a set of YPD agar plates with increasing concentration (0.74 mM and 1.98 mM) of lovastatin. The plates were incubated at 30°C for 3 days, after which the growth of the strains was recorded by photography.

10 SEQ ID NO: 1 represents the nucleotides of *mlcE* (coding sequence, from the compactin biosynthetic gene cluster (GenBank accession number: AB072893.1))

SEQ IN NO: 2 represents the nucleotides of *mlcE* (coding sequence, synthetic codon optimized version)

15

SEQ ID NO: 3 represents the nucleotides of *mlcE-mRFP* (coding sequence, synthetic codon optimized version of *mlcE* with mRFP fusion)

SEQ ID NO: 4 represents the nucleotides of *lovI/H* (coding sequence (GenBank
20 accession number: AF141925.1))

SEQ ID NO: 5 represents the nucleotides of *mokI* (coding sequence (GenBank accession number: DQ176595.1))

25 SEQ ID NO: 6 represents the nucleotides of the primer mlcE-F

SEQ ID NO: 7 represents the nucleotides of the primer mlcE-R

SEQ ID NO: 8 represents the nucleotides of the primer TEF1-d
30

SEQ ID NO: 9 represents the nucleotides of the primer PGK1-s

SEQ ID NO: 10 represents the nucleotides of the primer RFP_F+

SEQ ID NO: 11 represents the nucleotides of the primer RFP_R+

SEQ ID NO: 12 represents the nucleotides of the primer *mlcE*-RFP-R

5 SEQ ID NO: 13 represents the nucleotides of the primer RFP-F

SEQ ID NO: 14 represents the nucleotides of the primer C1_TADH1_F

SEQ ID NO: 15 represents the nucleotides of the primer PDR5-DEL-F

10

SEQ ID NO: 16 represents the nucleotides of the primer PDR5-DEL-R

SEQ ID NO: 17 represents the amino acids of *MlcE* (GenBank accession number: BAC20568.1)

15

SEQ ID NO: 18 represents the amino acids of *LovI/H* (GenBank accession number: AAD34558.1)

SEQ ID NO: 19 represents the amino acids of *MokI* (GenBank accession number: ABA02247.1)

20

SEQ ID NO: 20 represents the amino acids of *MlcE*-mRFP

The invention will now be described in further details in the following non-limiting
25 examples.

Example 1 (integration of the *mlcE* gene into *Saccharomyces cerevisiae*)

General setup

The *mlcE* gene was codon optimized and expressed from a genomic locus in
30 *Saccharomyces cerevisiae* as a single copy gene under the control of a strong
constitutive promoter (TEF1). The gene was introduced into a 'wild type' strain
and a *pdr5* deletion strain (*pdr* = Pleotropic Drug Resistance gene). The *pdr5* gene
encodes a pump that has shown to confer a basic level of statin-resistance in
Saccharomyces cerevisiae (Hirata & Yano, 1994; Riccardo & Kielland-Brandt,

2011). Furthermore, it has previously been shown that elimination of the *pdr5* gene sensitize the strain in question which, in turn, allows for a larger dynamic test range with respect to statin effects.

- 5 The efflux pump encoding gene *m/cE* was integrated into a defined locus of *Saccharomyces cerevisiae*, CEN.PK 113-11C (*MATa MAL2-8C SUC2 his3Δ ura3-52*), genome using a yeast expression platform established by Mikkelsen et al. 2012
- 10 The yeast strain CEN.PK 113-11C (*MATa MAL2-8C SUC2 his3Δ ura3-52*) was donated by Dr. Petter Kötter, Institut für Mikrobiologie, der Johan Wolfgang Goethe-Universität, Frankfurt am Main, Germany. *Escherichia coli*, DH5 α , was used to propagate the plasmids.
- 15 *The media*
Yeast strains were cultivated in standard liquid yeast peptone dextrose (YPD) or synthetic complete (SC) medium. Yeast transformants were selected on SC medium lacking uracil. Removal of the URA3 marker, via direct repeat recombination, was achieved by growing the strain on SC medium containing 740
20 mg/L 5-fluororotic acid (5-FOA) and 30 mg/L uracil. The *E. coli* transformants were selected on LB medium containing 100 μ g/mL ampicillin.

The inventors of the present application then tested yeast susceptibility to statins and statin-unrelated compounds by growing yeast strains on solid YPD medium
25 supplemented with compactin, lovastatin, simvastatin, pravastatin sodium, atorvastatin, mycophenolic acid (MPA) or vanillin respectively. Vanillin, MPA and atorvastatin stock solutions were prepared by dissolving the compounds in 99.9% ethanol followed by filter-sterilization. Compactin, lovastatin, and simvastatin were converted to their active forms.

30

More specifically, the solid compounds were dissolved in 1 mL 99% ethanol, preheated to 50°C, alkalized with 0.5 mL of 0.6 M NaOH and incubated at 50°C for 2 hours. The pH of the solutions was then adjusted to 7.2 by adding 0.4 M HCl. Final volume of all the solutions was adjusted to 2 mL with water, resulting in
35 stock solutions of 50 mM. The statin stock solutions were filter-sterilized and

stored at -20°C. Compactin and atorvastatin were purchased from Toronto Research Chemicals, lovastatin from Tokyo Chemical Industry, MPA and vanillin from Sigma-Aldrich, and simvastatin was purchased from Ark Pharm.

Compound	Concentration of the stock solution [mM]	Source
Compactin	50	Toronto Research Chemicals (Canada, Ontario, Toronto)
Lovastatin	50	Tokyo Chemical Industry (Japan, Tokyo)
Simvastatin	50	Ark Pharm (USA, Illinois, Libertyville)
Atorvastatin	10	Toronto Research Chemicals (Canada, Ontario, Toronto)
Vanillin	30	Sigma-Aldrich (USA, Missouri, St. Louis)
MPA	320	Sigma-Aldrich (USA, Missouri, St. Louis)

Plasmid construction

- 5 The *mlcE* gene was codon-optimized for expression in *Saccharomyces cerevisiae* (by the company Evolva). The codon-optimized version of the *mlcE* gene was amplified from plasmid pEN669 (source: Evolva) with primers mlcE-F and mlcE-R. Together with the TEF1 promoter, the amplified gene was cloned into the X-3 vector via USER cloning technique, resulting in plasmid pX3-TEF1-mlcE. To
- 10 determine the intracellular localization of MlcE, a red fluorescent protein (RFP) was fused to its C-terminus.

For that plasmid pX3-TEF1-mlcE-RFP and a control plasmid pX3-TEF1-RFP were constructed: *mlcE* without the stop codon was amplified from plasmid pEN669

15 using primers mlcE-F and mlcE-RFP-R, and RFP was amplified from plasmid pWJ1350 using either RFP-F (for tagging mlcE) or RFP_F+ (for the control plasmid) and RFP_R+ primers. All fragments were amplified by PCR using a USER cloning compatible PfuX7 polymerase.

Table: List of plasmids used

Name	Description	Reference
pEN669	mlcE template	Purchased from Evolva
pWJ1350	RFP template	Lisby et al. 2003
pSP-G2	PGK1,TEF1 template	Partow et al. 2010
pX3 TEF1 mlcE	Plasmid carrying a gene-targeting cassette for expressing mlcE in yeast.	This study
pX3 TEF1- RFP	Plasmid carrying a gene-targeting cassette for expressing RFP-tagged mlcE in yeast.	This study
pX3 TEF1 mlcE RFP	Plasmid carrying a gene-targeting cassette for expressing RFP in yeast.	This study

5

Strain construction

The constructed plasmids were digested with the NotI restriction enzyme (purchased from New England Biolabs), and the linear fragments were used for yeast transformation using the lithium acetate/polyethylene glycol/single carrier DNA transformation method. The URA3 marker in all the constructed strains was excised by direct repeat recombination, and the correct integrations of the gene were verified by colony PCR with one primer annealing in the yeast genome next to the integration site, and one primer annealing inside the introduced DNA.

15 Targeted deletion of the pleiotropic drug resistance pump (*pdr5*) encoding gene in the reference and X3::TEF1-mlcE expressing strains was performed, as described by Güldener et al 1996, using the primers PDR5-DEL-F and PDR5-DEL-R.

Table: list of strains used

Name	Genotype	Reference
CEN.PK113-11C	MAT α MAL2-8C SUC2 his3 Δ ura3-52	Kindly donated by Dr. Petter Kötter, Institut für Mikrobiologie, der Johan Wolfgang Goethe-Universität, Frankfurt am Main, Germany
ARX3	MAT α MAL2-8C SUC2 his3 Δ ura3-52 X3(pTEF1-mlcE)	This study
pdr5 Δ	MAT α MAL2-8C SUC2 his3 Δ ura3--52 pdr5 Δ	This study
AR29pdr5 Δ	MAT α MAL2-8C SUC2 his3 Δ ura3-52 X3(pTEF1-mlcE)	This study
ARX1	MAT α MAL2-8C SUC2 his3 Δ ura3-52 (pTEF1-mlcE-RFP)	This study
ARX2	MAT α MAL2-8C SUC2 his3 Δ ura3-52 (pTEF1-RFP)	This study

5 Example 2 (phylogenetic tree)

An initial sequence comparison investigation of the putative efflux pump MlcE from the compactin biosynthetic gene cluster using Standard Protein BLAST showed that this protein strongly resembles some of the known export proteins from the major facilitator superfamily (MFS), such as crystal violet efflux pump

10 Sge1 from *Saccharomyces cerevisiae* and HC-toxin efflux pump ToxA from *Cochliobolus carbonum*. Moreover, prediction of MlcE topology using the TOPCONS server suggested that MlcE comprises 14 transmembrane-spanning regions (TMS), possibly classifying MlcE to the Drug:H⁺ antiporter 2 family (DHA2; 14

15 TMS) of the MFS drug transporters, a family which ToxA and Sge1 belong to as well. The inventors of the present application constructed a phylogenetic tree, which suggests that MlcE, together with its orthologs from the lovastatin and monacolin biosynthetic gene clusters, LovI and MkI, respectively, does indeed belong to the DHA2 family of drug resistance proteins with 14 TMS (Figure 1).

Table: Proteins used for the phylogenetic tree construction

Protein	Microorganism	Representative Substrate	Accession Number (UniProtKB)
MFS-DHA2 (14 TMS)			
ToxA	<i>Cochliobolus carbonum</i>	HC-toxin	Q00357
Tri12	<i>Fusarium sporotrichioides</i>	Trichotechene	O93842
CFP	<i>Cercospora kikuchii</i>	Cercosporin	O93886
Atr1	<i>Saccharomyces cerevisiae</i>	Aminotriazole	P13090
Sge1	<i>Saccharomyces cerevisiae</i>	Crystal violet	P33335
EmrB	<i>Escherichia coli</i>	CCCP ^b	P0AEJ0
LfrA	<i>Mycobacterium smegmatis</i>	Acriflavin	Q50392
QacA	<i>Staphylococcus aureus</i>	Benzalkonium chloride	Q1XG09
SmvA	<i>Salmonella typhimurium</i>	Ethidium bromide	P37594
ActVa 1	<i>Streptomyces coelicolor</i>	Actinochodrin	Q53903
CmcT	<i>Nocardia lactamdurans</i>	Cephameycin	Q04733
Mmr	<i>Streptomyces coelicolor</i>	Methylenomycin A	P11545
Pur8	<i>Streptomyces lipmanii</i>	Puromycin	P42670
MFS - DHA 1 (12 TMS)			
Ctb4	<i>Cercospora nicotinae</i>	Cercosporin	A0ST42
CefT	<i>Acremonium chrysogenum</i>	Cephalosporin	Q8NKG7
Mdr1	<i>Candida albicans</i>	Fluconazole	P28873

Flu1	<i>Candida albicans</i>	Fluconazole	G1UB37
Bcr	<i>Escherichia coli</i>	Bicyclomycin	C6EA15
Blt	<i>Bacillus subtilis</i>	Acriflavin	M1U4Q0
EmrD	<i>Escherichia coli</i>	CCCP ^b	P31442
CaMDR1	<i>Candida albicans</i>	Benomyl	Q9URI2
NorA	<i>Staphylococcus aureus</i>	Acriflavin	P0A0J7
CyhR	<i>Candida maltosa</i>	Cycloheximine	P32071
CmlA	<i>Pseudomonas aeruginosa</i>	Chloramphenicol	Q83V15
Flr1	<i>Saccharomyces cerevisiae</i>	Fluconazole	P38124
Tpo1	<i>Saccharomyces cerevisiae</i>	Spermine	Q07824
Dtr1	<i>Saccharomyces cerevisiae</i>	Dityrosine	P38125
Aqr1	<i>Saccharomyces cerevisiae</i>	Quinidine	P53943
Statin Efflux pumps - unknown family			
MlcE	<i>Penicillium citrinum</i>	Compactin	Q8J0F3
LovI	<i>Aspergillus terreus</i>	Lovastatin	Q9Y7D4
MkI	<i>Monascus pilosus</i>	Monacolin	Q3S2U5

Example 3 (toxicity analysis on dilution tests)

- 5 The constructed strains response to different lovastatin levels present in the growth medium were tested using a agar-plate dilution assay (also known as a spot assay). Overnight cultures of the four *Saccharomyces cerevisiae* strains (wt, ARX3, AR29 *pdv5Δ*, *pdv5Δ*,) were diluted to OD₆₀₀ of 0.2 and a fivefold dilution series for each strain was made. Four microliters of each dilution were deposited
- 10 on a series of agar plates with different concentrations of activated lovastatin (0 mM, 0.74 mM, 1.98 mM). The idea behind this assay is that it allows for

reproducible testing of toxic effects by observing at which dilution steps the different strains are able to form visible colonies, under a given concentration of the toxic compound. The growth of the individual strain as a function of time was recorded by photography.

5

The plate assay (figure 4) confirmed that the *pdr5Δ* strain is more sensitive to lovastatin than the wild type (wt), as evidenced by the lack of growth even at the lowest tested concentration (0.74 mM). Expression of the *mlcE* gene allows both the wild type and *pdr5Δ* strain to grow at elevated statin concentrations and at
10 the higher dilutions evidencing that the MlcE efflux pump indeed can provide statin resistance in yeast cells, such as *Saccharomyces cerevisiae*.

Example 4 (subcellular localization of the MlcE efflux pump)

15 To determine the subcellular localization of the MlcE efflux pump *in Saccharomyces cerevisiae* and in order to test the hypothesis that the MlcE protein is in fact a transmembrane efflux pump, the inventors of the present application constructed a C-terminal mRFP fusion and expressed it from the same locus in *Saccharomyces cerevisiae*. The resulting strain was analyzed by
20 fluorescent microscopy and compared to a *Saccharomyces cerevisiae* strain that expressed mRFP (cytoplasmic localization) from the same promoter and the same locus as the strain with the RFP-tagged MlcE.

More specifically, the MlcE was tagged with RFP at the C- terminus, and integrated
25 into the previously described site in the yeast genome under the control of TEF1 promoter, resulting in the yeast strain ARX1 (Figure 2A). Fluorescent microscopy of ARX1 revealed a ring-like distribution of fluorescence around the cell (Figure 2B top panel), indicating that the tagged putative efflux pump was localized in the plasma membrane. In contrast, the mRFP alone was found to have a uniform
30 cytoplasmic distribution in the control cells ARX2 (Figure 2B bottom panel), expressing RFP alone from the same locus and controlled by the promoter as in strain ARX1. These results support the prediction that MlcE is a trans-membrane protein and shows that the protein is targeted to the plasma membrane in *S. cerevisiae*.

35

Moreover, to determine if the putative efflux pump MlcE has the ability to export statins across the plasma membrane the inventors of the present application also tested whether MlcE confers resistance to statins in yeast. To achieve that, *mlcE* was expressed from a defined genomic locus in *Saccharomyces cerevisiae* as a
5 single copy gene under the control of a strong constitutive promoter pTEF1 (Figure 2A). The resulting yeast strain ARX3 was tested for susceptibility to compactin by serial dilution plating of both wild type (WT) and ARX3 strains on YPD agar plates supplemented with the active form of compactin (Figure 3). The efflux pump harbouring strain ARX3 showed an increased resistance to compactin
10 present in the medium compared to the wild type strain, suggesting that MlcE is indeed a compactin efflux pump capable of exporting this natural statin out of the cells and not into storage compartments such as the vacuole.

15 **Example 5 (the MlcE pump in *Saccharomyces cerevisiae* confers resistance against other types of statins)**

The inventors of the present application additionally showed that *Saccharomyces cerevisiae* strains with the inserted transmembrane efflux pump MlcE had an increased resistance not only to compactin but also to the other natural statin,
20 lovastatin, when compared to the wild type yeast strain.

In addition to this, the inventors of the present application surprisingly found that introduction of the transmembrane efflux pump MlcE into *Saccharomyces cerevisiae* strains also resulted in increased resistance to the semi-natural statin
25 simvastatin, when compared to the wild type yeast strain.

In contrast, MlcE does not seem to have the ability to export compounds, which are structurally unrelated to its natural substrate compactin, namely atorvastatin, vanillin and mycophenolic acid (MPA) because ARX3 strain does not show an
30 increased resistance to these compounds (Figure 3).

On this basis the inventors of the present application concluded that MlcE is not a multi-drug resistance efflux pump such as for example Pdr5 and Sge1 from *Saccharomyces cerevisiae* but rather a transmembrane statin specific efflux
35 pump.

In general this means that the efflux pump MlcE provides resistance to both, natural and semi-natural statins, making it a great tool for optimizing yeast cell factories for statin production.

References

- (1) Xu W. et al., (2013), "*LovG: The Thioesterase Required for Dihydromonacolin*", *Angew. Chem. Int. Ed.* 2013, 52, 6472 –6475.
- 5
- (2) Abe et al. (2002), "*Molecular cloning and characterization of an ML-236B (compactin) biosynthetic gene cluster in Penicillium citrinum*" *Mol. Genet. Genomics* (2002) 267: 636–646.
- 10
- (3) Hirata D., & Yano K. (1994), "*Saccharomyces cerevisiae YDR1, which encodes a member of the ATP-binding cassette (ABC) superfamily, is required for multidrug resistance*", *Curr. Genet* (1994) 26:285-294.
- (4) Riccardo L., & Kielland-Brandt MC. (2011), "*Sensitivity to Lovastatin of*
- 15 *Saccharomyces cerevisiae Strains Deleted for Pleiotropic Drug Resistance (PDR) Genes*", *J Mol Microbiol Biotechnol* 2011;20:191–195.
- (5) Hutchinson et al., (2000), "*Aspects of the biosynthesis of non-aromatic fungal polyketides by iterative polyketide synthases*" *Antonie van Leeuwenhoek* 78: 287–
- 20 295.
- (6) Mikkelsen et al. (2012), "*Microbial production of indolylglucosinolate through engineering of a multi-gene pathway in a versatile yeast expression platform*", *Metabolic Engineering* 14 (2012) 104–111.
- 25
- (7) Partow S. et al. (2010), "*Characterization of different promoters for designing a new expression vector in Saccharomyces cerevisiae*" *Yeast* 2010; 27: 955–964.
- (8) Lisby M. et al. (2003), "*Colocalization of multiple DNA double-strand breaks at*
- 30 *a single Rad52 repair centre*", *Nature Cell Biology*, vol. 5, no. 6, June 2003.
- (9) Güldener U. et al. (1996), "*A new efficient gene disruption cassette for repeated use in budding yeast*", *Nucleic Acids Research*, 1996, Vol. 24, No. 13 2519–2524.

Claims

1. Method for the production of statin in a transgenic microorganism, wherein the method comprises expression in said microorganism of one or more
5 polynucleotide(s) encoding one or more transmembrane statin efflux pump(s).
2. Method according to claim 1, wherein the polynucleotide(s) are chosen from the group consisting of SEQ ID NOs: 1, 2, 3, 4 and/or 5.
- 10 3. Method according to claim 2, wherein the polynucleotide(s) comprise(s) one or more nucleotide variant(s) comprising sequences with a degree of identity to any of SEQ ID NOs: 1, 2, 3, 4 and/or 5 of at least: 80%, preferably at least 85%, more preferably at least 90%, still more preferably at least 95%, still more preferably at least 97%, still more preferably at least 98%, most preferably at
15 least 99%.
4. Method according to any of claims 2 or 3, wherein one or more of the polynucleotide(s) according to SEQ ID NOs: 1, 2, 3, 4 and/or 5 is/are overexpressed and/or wherein one or more of the polynucleotide variant(s)
20 according to claim 3 are overexpressed.
5. Method according to any of claims 1-4, wherein the transgenic microorganism is a non-filamentous fungus.
- 25 6. Method according to claim 5, wherein the non-filamentous fungus is selected from the group consisting of *Saccharomyces cerevisiae*, *Pichia pastoris* and *Schizosaccharomyces pomp*.
7. Statins produced by a method according to any of claims 1-6.
30
8. Transgenic microorganism for use in the production of statin, wherein the microorganism comprises one or more polynucleotide(s) encoding one or more transmembrane statin efflux pump(s).

9. Transgenic microorganism according to claim 8, wherein the polynucleotide(s) is/are chosen from the group consisting of SEQ ID NOs: 1, 2, 3, 4 and/or 5.
10. Transgenic microorganism according to claim 9, wherein the polynucleotide(s) comprises one or more nucleotide variant(s) comprising sequences with a degree of identity to any of SEQ ID NOs: 1, 2, 3, 4 and/or 5 of at least: 80%, preferably at least 85%, more preferably at least 90%, still more preferably at least 95%, still more preferably at least 97%, still more preferably at least 98%, most preferably at least 99%.
11. Transgenic microorganism according to any of claims 9 or 10, wherein one or more of the polynucleotide(s) according to SEQ ID NOs: 1, 2, 3, 4 and/or 5 is/are overexpressed and/or wherein one or more of the polynucleotide variants according to claim 10 is/are overexpressed.
12. Transgenic microorganism according to any of claims 8 or 11, wherein the transgenic microorganism is a non-filamentous fungus.
13. Transgenic microorganism according to claim 12, wherein the non-filamentous fungus is selected from the group consisting of *Saccharomyces cerevisiae*, *Pichia pastoris* and *Schizosaccharomyces pomp*.
14. Use of a transmembrane statin efflux pump in a transgenic non-filamentous statin-producing microorganism, for the:
- (i) production of statins in the microorganism and/or
 - (ii) increasing the statin resistance in the microorganism and/or
 - (iii) decreasing the statin self-intoxication in the microorganism and/or
 - (iii) increasing the export of the produced statins into the extracellular medium
15. Use of the statins obtained in any one of claims 1 to 7 in the production of a medicament.




Figure 1:
Phylogenetic tree




Figure 2:
Strain construction and subcellular localization




Figure 3: Investigation of the potential of MlcE to confer the resistance to statins in yeast




Figure 4:
Investigation of the potential of MlcE to complement the PDR5 efflux pump in yeast

INTERNATIONAL SEARCH REPORT

International application No PCT/DK2015/050098

A. CLASSIFICATION OF SUBJECT MATTER INV. A61K36/06 A61K31/366 ADD. A61K31/20		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, EMBASE, FSTA, WPI Data, Sequence Search, BIOSIS		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2009/133089 A1 (DSM IP ASSETS BV [NL]; VAN DEN BERG MARCO ALEXANDER [NL]; HANS MARCUS) 5 November 2009 (2009-11-05) page 3, lines 12-24 page 11, line 33 - page 12, line 21 -----	1-3, 5-10,12, 13
X	US 2003/078395 A1 (ABE YUKI [JP] ET AL) 24 April 2003 (2003-04-24) page 1, paragraphs 3,11 - page 2, paragraphs 14,16 page 5, paragraphs 63,64 page 18, paragraph 262 - page 19, paragraph 274 page 20, paragraph 302 - page 21, paragraph 309 sequence 37 -/--	1-15
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents :		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	
"P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search	Date of mailing of the international search report	
1 July 2015	31/07/2015	
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Bonello, Steve	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK2015/050098

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. forming part of the international application as filed:
 - in the form of an Annex C/ST.25 text file.
 - on paper or in the form of an image file.
 - b. furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
 - c. furnished subsequent to the international filing date for the purposes of international search only:
 - in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
 - on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2. In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No

PCT/DK2015/050098

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>& DATABASE EMBL [Online]</p> <p>9 October 2006 (2006-10-09), "Sequence 37 from patent US 7056710.", retrieved from EBI accession no. EM_PAT:AR917484 Database accession no. AR917484 sequence</p> <p>-----</p> <p>US 2005/227262 A1 (CHEN YI-PEI [TW] ET AL) 13 October 2005 (2005-10-13)</p> <p>sequence 26 page 1, paragraph 3 page 3, paragraph 40; table 1 page 7, paragraph 87 - page 8, paragraph 88</p> <p>& DATABASE EMBL [Online]</p>	1-5, 7-10,14, 15
X	<p>15 February 2009 (2009-02-15), "Sequence 26 from patent US 7482157.", retrieved from EBI accession no. EM_PAT:GP057816 Database accession no. GP057816 sequence</p> <p>-----</p> <p>US 6 949 356 B1 (BUSBY ROBERT [US] ET AL) 27 September 2005 (2005-09-27)</p> <p>column 2, lines 41,54 column 3, line 18 column 27, lines 36-49 column 29, lines 30-36 column 48, lines 18-35 column 49, line 65 - column 50, line 12 column 51, lines 6-20 sequence 21</p>	1-3, 7-10,14, 15
A	<p>FORMENTI LUCA RICCARDO ET AL: "Sensitivity to Lovastatin of Saccharomyces cerevisiae Strains Deleted for Pleiotropic Drug Resistance (PDR) Genes", JOURNAL OF MOLECULAR MICROBIOLOGY AND BIOTECHNOLOGY, vol. 20, no. 4, 12 July 2011 (2011-07-12), pages 191-195, XP009180693, ISSN: 1464-1801, DOI: 10.1159/000329068 [retrieved on 2011-07-12] abstract</p> <p>-----</p>	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/DK2015/050098

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2009133089 A1	05-11-2009	CN 102014894 A EP 2271335 A1 US 2011054193 A1 WO 2009133089 A1	13-04-2011 12-01-2011 03-03-2011 05-11-2009
US 2003078395 A1	24-04-2003	AR 034550 A1 AT 373101 T AU 783319 B2 AU 3709201 A BR 0101518 A CA 2342397 A1 CN 1325959 A CY 1106985 T1 CZ 20011367 A3 DE 60130394 T2 DK 1149919 T3 EP 1149919 A2 ES 2293966 T3 HK 1037683 A1 HU 0101569 A2 IL 142619 A KR 100632174 B1 MX PA01003913 A NO 20011890 A NZ 511166 A PL 347118 A1 PT 1149919 E RU 2236463 C2 TW I312807 B US 2003078395 A1 US 2005214909 A1 US 2007111293 A1	03-03-2004 15-09-2007 13-10-2005 25-10-2001 13-11-2001 18-10-2001 12-12-2001 26-09-2012 12-12-2001 19-06-2008 03-12-2007 31-10-2001 01-04-2008 21-12-2007 29-05-2002 20-03-2008 11-10-2006 20-08-2003 19-10-2001 26-11-2002 22-10-2001 17-12-2007 20-09-2004 01-08-2009 24-04-2003 29-09-2005 17-05-2007
US 2005227262 A1	13-10-2005	CN 1637143 A DE 102004062386 A1 FR 2864548 A1 FR 2883297 A1 JP 2005185283 A KR 20050065437 A TW I297358 B US 2005227262 A1	13-07-2005 29-09-2005 01-07-2005 22-09-2006 14-07-2005 29-06-2005 01-06-2008 13-10-2005
US 6949356 B1	27-09-2005	AU 1215401 A CA 2388427 A1 EP 1237914 A1 JP 2003512039 A US 6949356 B1 US 2002128250 A1 US 2009075327 A1 WO 0129073 A1	30-04-2001 26-04-2001 11-09-2002 02-04-2003 27-09-2005 12-09-2002 19-03-2009 26-04-2001